Comparing the current results to its competitors, Trisalus Life Sciences Inc reported Revenue decrease in the 1 quarter 2026 year on year by -0.03 %, despite the revenue increase by the most of its competitors of 6.85 %, recorded in the same quarter.
Trisalus Life Sciences Inc 's Comment on Competition and Industry Peers
The company competes with other firms that have significantly greater financial, marketing, sales, technology, or business resources. These competitors may pursue similar business opportunities or arrangements, which could affect the company's ability to secure such transactions on favorable terms or at all. The impact of weather conditions and natural disasters on competitors varies based on the locations of their suppliers and operations. Additionally, if the company's product candidates receive approval, it will compete with other cancer therapies in sales and marketing. Competitors may also develop similar or alternative product candidates that do not infringe on the company's patents.
August 28, 2025
Transforming Oncology: TriSalus Life Sciences Unveils Innovations and Financial Progress Amid Upcoming Investor Engagements TriSalus Life Sciences Inc. (Nasdaq: TLSI), an emerging leader in oncology focused on redefining the treatment landscape for solid tumors, has been making significant strides in both its technological advancements and financial performance. Headquartered in Westminster, Colorado, TriSalus specializes in integrating innovative delivery systems with standard-of-care therapies, aiming to enhance the therapeutic efficacy and improve outcomes for patients battling formidable cancers.In a notable move to engage with the investment community, Mary Szela, Chief Executive Officer and President, ...
September 23, 2024
In a significant development in the field of oncology, TriSalus Life Sciences, Inc. announced the publication of new research that highlights the effectiveness of its innovative drug delivery system in targeting solid tumors. The study, recently published in the Journal of Vascular and Interventional Radiology , provides evidence that the Pressure-Enabled Drug Delivery (PEDD) method significantly enhances the therapeutic delivery of glass microspheres to liver tumors in a porcine model. Key FindingsThe research demonstrates a promising new approach to treating liver and pancreatic tumors, which are notoriously difficult to target due to their unique vascular environments. The TriNav Infusion System, which e...
June 27, 2024
TriSalus Life Sciences Announces Results of Exchange Offer and Consent Solicitation for WarrantsTriSalus Life Sciences Inc., an oncology company focused on improving treatment for patients with liver and pancreatic tumors, has announced the expiration and results of its exchange offer and consent solicitation relating to its warrants. The company aims to integrate its innovative delivery technology with immunotherapy to transform cancer treatment.The exchange offer and consent solicitation commenced by TriSalus Life Sciences entailed the offer to exchange its warrants identified in the Prospectus/Offer to Exchange. The purpose of this initiative is to streamline the company s capital structure and enhance it...
June 3, 2024
Delivering Hope: TriSalus Life Sciences Innovative Approach in Combating Liver and Pancreatic Cancers In a landscape where advances in oncology are often measured in incremental steps, TriSalus Life Sciences, Inc. (Nasdaq: TLSI) is making significant strides. The company, known for integrating their novel Pressure-Enabled Drug Delivery (PEDD) technology with immunotherapy, presented compelling data from their Phase 1b PERIO-02 clinical trial at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. This data could mark a turning point in the treatment landscape for liver and pancreatic tumors, conditions notoriously difficult to treat with conventional methods. Unveiling Promising DataThe PER...
Publicly Traded Peers of Trisalus Life Sciences Inc
Anika Therapeutics Inc Share Performance
+122.57%
This Year
Anika Therapeutics Inc
Profile
Anika Therapeutics Inc is a medical technology company that focuses on developing and commercializing therapeutic products to treat tissue-related disorders. Their business model revolves around conducting extensive research and development to create innovative therapies, partnering with healthcare professionals and distributors to bring their products to market, and generating revenue through the sale of these products worldwide. They also collaborate with other companies and academic institutions to enhance their product portfolio and expand their reach in the healthcare industry.
Merck & Co. Inc. operates primarily as a research-driven pharmaceutical company, focused on the development, manufacturing, and marketing of prescription drugs and vaccines globally. It aims to address unmet medical needs through innovative research, collaborations, and rigorous clinical trials, while promoting patient well-being and contributing to global healthcare with high-quality, affordable medications.
Johnson & Johnson operates as a multinational healthcare company with a diversified business model that spans pharmaceuticals, medical devices, and consumer health products. By focusing on innovation and strategic acquisitions, the company aims to improve global health and well-being.
Gilead Sciences Incs business model centers on researching, developing, and marketing innovative medicines, primarily targeting antiviral therapies. They focus on addressing unmet medical needs to enhance patient health globally.
Bristol Myers Squibb Company operates a research and development-driven business model, focusing on the discovery and delivery of innovative medicines for various diseases. It emphasizes collaboration with academic institutions, government entities, and other pharmaceutical firms to enhance its therapeutic portfolio and improve patient outcomes.
Sources:
Trisalus Life Sciences Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Trisalus Life Sciences Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
